

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

| Drug | Mesalazine |
|-----------------------------|--|
| Brand Name | Mezera™ |
| Dosage Forms | 1 g/actuation foam enema, 1 g suppository |
| Manufacturer | Avir Pharma |
| Submission Type | Line Extension |
| Use Reviewed | Foam enema: treatment of mildly active ulcerative colitis of the sigmoid colon and rectum. Suppository: treatment of acute mild to moderate ulcerative proctitis. |
| Common Drug Review (CDR) | No, CDR did not review. |
| Provincial Review | The Drug Benefit Council (the DBC) does not review drugs submitted as Line Extensions. |
| Drug Coverage | Non-Benefit |
| Decision | |
| Date | February 26, 2019 |
| Reasons | Mezera foam enema and suppository did not demonstrate advantages over existing mesalazine formulations with respect to efficacy, safety and quality of life. |
| | Based on existing PharmaCare coverage of mesalazine comparators and clinician feedback, Mezera was assessed to have a minimal role with regard to fulfilling current unmet clinical needs in British Columbia. |
| | • Based on economic considerations and the submitted product price, Mezera foam enema is more costly than available alternatives. |
| Other Information | None |

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the <u>Drug Benefit Council (DBC)</u> gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the <u>Common Drug Review (CDR)</u>
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the The Drug Review Process in B.C. - Overview and Ministry of Health - PharmaCare for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.